179 related articles for article (PubMed ID: 35708257)
1. Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year.
Galluzzo M; Talamonti M; Bernardini N; Chiricozzi A; De Simone C; Bonifati C; Bruni P; Diotallevi F; Esposito M; Graceffa D; Hansel K; Loconsole F; Moretta G; Mugheddu C; Papini M; Richetta A; Skroza N; Atzori L; Fargnoli MC; Persechino S; Offidani A; Stingeni L; Peris K; Potenza C; Bianchi L
Expert Opin Biol Ther; 2022 Dec; 22(12):1585-1592. PubMed ID: 35708257
[TBL] [Abstract][Full Text] [Related]
2. Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks.
Galluzzo M; Marcelli L; Vellucci L; Paganini C; Maffei V; Tofani L; Belcastro A; Bianchi L; Talamonti M
Expert Opin Biol Ther; 2023 Apr; 23(4):371-381. PubMed ID: 36971507
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Del Alcázar E; López-Ferrer A; Martínez-Doménech Á; Ruiz-Villaverde R; Llamas-Velasco MDM; Rocamora V; Julià M; Notario J; Fernández-Freire LR; Sahuquillo-Torralba A; Vidal D; Rivera R; Carretero G; Mateu A; de la Cueva P; Carrascosa JM
Dermatol Ther; 2022 Feb; 35(2):e15231. PubMed ID: 34820971
[TBL] [Abstract][Full Text] [Related]
4. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence.
Medina-Catalán D; Riera P; Pagès-Puigdemont N; Masip M; López-Ferrer A; Vilarrasa E; Puig L
Int J Clin Pharm; 2022 Jun; 44(3):725-730. PubMed ID: 35380392
[TBL] [Abstract][Full Text] [Related]
5. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
Gargiulo L; Ibba L; Malagoli P; Angileri RG; Bardazzi F; Bernardini N; Burlando M; Carrera CG; Chiricozzi A; Dapavo P; Dini V; Fabbrocini G; Gaiani FM; Galluzzo M; Giofré C; Guarneri C; Loconsole F; Malara G; Marcelli L; Megna M; Piaserico S; Talamonti M; Costanzo A; Narcisi A
J Eur Acad Dermatol Venereol; 2023 May; 37(5):1017-1027. PubMed ID: 36695061
[TBL] [Abstract][Full Text] [Related]
6. Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis.
Mälkönen T; Nuutinen P; Hallinen T; Soini E; Nissinen R; Wennerstöm C; Rantanen T; Hagman JH; Harvima R; Höök-Nikanne J; Ilves T; Lintu P; Malanin K; Soramäki I; Tasanen K; Teho A; Vähävihu K; Itälinna S; Leinonen P; Sarajärvi P; Huilaja L; Pasternack R
Acta Derm Venereol; 2022 Jan; 102():adv00631. PubMed ID: 34904684
[TBL] [Abstract][Full Text] [Related]
7. Real-life experience of guselkumab in patients with psoriasis.
Snast I; Sherman S; Holzman R; Hodak E; Pavlovsky L
Dermatol Ther; 2020 Nov; 33(6):e13964. PubMed ID: 32618384
[TBL] [Abstract][Full Text] [Related]
8. Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study.
Galluzzo M; Tofani L; Lombardo P; Petruzzellis A; Silvaggio D; Egan CG; Bianchi L; Talamonti M
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32659978
[TBL] [Abstract][Full Text] [Related]
9. Absolute Psoriasis Area and Severity Index as a valuable marker to determine initial treatment response in psoriasis patients treated with guselkumab in routine clinical care.
Seidl U; Pinter A; Wilsmann-Theis D; Poortinga S; Morrison K; Mrowietz U; Gerdes S
Dermatol Ther; 2022 Jan; 35(1):e15193. PubMed ID: 34741783
[TBL] [Abstract][Full Text] [Related]
10. Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial.
Puig L; Costanzo A; de Jong EMGJ; Torres T; Warren RB; Wapenaar R; Wegner S; Gorecki P; Gramiccia T; Jazra M; Buyze J; Conrad C
Am J Clin Dermatol; 2024 Mar; 25(2):315-325. PubMed ID: 37804472
[TBL] [Abstract][Full Text] [Related]
11. Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience.
Bardazzi F; Viviani F; Merli Y; Di Lernia V; Peccerillo F; Conti A; Lasagni C; Tabanelli M; D'Adamio S; Di Nuzzo S; Cortellazzi C; Filippi F
Expert Opin Biol Ther; 2022 Dec; 22(12):1561-1566. PubMed ID: 35388713
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of guselkumab in patients with moderate-to-severe plaque psoriasis: a retrospective study from China.
Huang H; Liu H; Zhu Z; Wang W; Liang B; Tang H; Yang S; Sheng Y; Sun L; Zhang X
Eur J Dermatol; 2024 Feb; 34(1):73-78. PubMed ID: 38557462
[TBL] [Abstract][Full Text] [Related]
14. Single-Centre Real-Life Experience of Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis.
Marletta D; Murgia G; Cattaneo A; Carrera C; Marzano A
J Drugs Dermatol; 2022 Aug; 21(8):864-866. PubMed ID: 35946964
[TBL] [Abstract][Full Text] [Related]
15. Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation.
Herranz-Pinto P; Alonso-Pacheco ML; Feltes-Ochoa R; Mayor-Ibarguren A; Servera-Negre G; Busto-Leis JM; Gonzalez-Fernández MA; Herrero-Ambrosio A
Clin Drug Investig; 2023 Jul; 43(7):517-527. PubMed ID: 37402097
[TBL] [Abstract][Full Text] [Related]
16. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
17. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
Blauvelt A; Leonardi C; Elewski B; Crowley JJ; Guenther LC; Gooderham M; Langley RG; Vender R; Pinter A; Griffiths CEM; Tada Y; Elmaraghy H; Lima RG; Gallo G; Renda L; Burge R; Park SY; Zhu B; Papp K;
Br J Dermatol; 2021 Jun; 184(6):1047-1058. PubMed ID: 32880909
[TBL] [Abstract][Full Text] [Related]
18. Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study.
Mastorino L; Siliquini N; Avallone G; Zenone M; Ortoncelli M; Quaglino P; Dapavo P; Ribero S
Dermatol Ther; 2022 Oct; 35(10):e15670. PubMed ID: 35762118
[TBL] [Abstract][Full Text] [Related]
19. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
20. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab.
Gerdes S; Asadullah K; Hoffmann M; Korge B; Mortazawi D; Wegner S; Personke Y; Gomez M; Sticherling M
J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1568-1577. PubMed ID: 35569014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
